University of Louisville homepage
All experts
All experts

Ashutosh Barve

Professor Term

School of Medicine

  • Professor Term
    School of Medicine

SPONSORED PROJECTS

  • Showing page 1 out of 1
Showing page 1, sponsored projects 1 to 19 of 19
GRANT
AWD-00000363\/|GS-US-567-6968 - Phase 1\/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta
Syneos Health_SH (SPN-001377)1 Jan 2026 - 31 Dec 2031
MORELEARN MORE
GRANT
AWD-00000071||A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY EVALUATING THE SAFETY AND EFFICACY OF EFRUXIFERMIN IN SUBJECTS WITH COMPENSATED CIRRHOSIS DUE TO NONALCOHOLIC STEATOHEPATITIS (NASH)\/METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH)
SC Liver Research Consortium_SCLRC (SPN-000274)1 Jan 2025 - 9 Jan 2030
MORELEARN MORE
GRANT
240193|ADX-629-ALH-001 - A Phase 2 Clinical Trial Investigating the Safety and Efficacy of ADX-629 in Subjects with Alcoholic Hepatitis
Medpace Inc_MPI5 Jan 2024
MORELEARN MORE
GRANT
240768| AK-US-001-0105 - A Phase 3, Randomized, Double-blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Non- Cirrhotic Subjects with Nonalholic Steatohepatitis (NASH) and Fibrosis
SC Liver Research Consortium_SCLRC1 Jan 2024 - 31 Dec 2033
MORELEARN MORE
GRANT
240242|ALT-801-203 - A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Pemvidutide in Non-Cirrhotic Subjects with Nonalcoholic Steatohepatitis (NASH)
Biorasi LLC_BLLC11 Aug 2023
MORELEARN MORE
GRANT
230905|CB8025-41837 AFFIRM: A Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients with Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
PPD Clinical Research Services_PCR (SPN-000559)10 Feb 2023 - 10 Jan 2028
MORELEARN MORE
GRANT
220389|LAM-2018-01 - Prospective Clinical Trial to Detect Liver Cancer through Quantification of cfDNA Methylation in Blood Samples (CLiMB) Protocol LAM-2018-01
SC Liver Research Consortium_SCLRC2 Aug 2022
MORELEARN MORE
GRANT
210959|PZA84215/C-00044 A Prospective, Randomized, Double-Blind, Sham-Controlled, Multi-Center Pivotal Study to Evaluate the Efficacy and Safety of Duodenal Mucosal Resurfacing Using the Revita System in Subjects with Type 2 Diabetes on Insulin therapy
IQVIA RDS Inc_IQVIA6 Jan 2022
MORELEARN MORE
GRANT
220271|GT-031 -A Seamless, Adaptive, Phase 2b/3, DB, Randomized, Placebo-controlled, MC, International Study Evaluating the Efficacy and Safety of Belapectin (GR-MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Labcorp Drug Development_LABCORP1 Jan 2022
MORELEARN MORE
GRANT
230035|C928-011: A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in Subjects with Alcoholic Hepatitis
DURECT Corporation_DCORP1 Jan 2022
MORELEARN MORE
GRANT
A0001-1 Created in Error - 220541|RNLC3131 - A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Delay of Encephalopathy Decompensation in Chirrhosis (RED-C)
Salix Pharmaceuticals Inc_SALIX1 Jan 2022 - 31 Dec 2027
MORELEARN MORE
GRANT
220389|Prospective Clinical Trial to Detect Liver Cancer through Quantification of cfDNA Methylation in Blood Samples (CLiMB) Protocol LAM-2018-01
SC Liver Research Consortium_SCLRC1 Jan 2021 - 31 Dec 2024
MORELEARN MORE
GRANT
200277|ARMOR - A Phase 3/4, Multinational, Multicenter, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Aramchol in Subjects with Nonalcoholic Steatohepatitis (ARMOR Study)
Covance_COV1 Jan 2020
MORELEARN MORE
GRANT
180350|REFINE 19244 Regorafenib observational study in hepatocellular carcinoma (the NIS Study) Bayer REFINE
IQVIA RDS Inc_IQVIA1 Jan 2018
MORELEARN MORE
GRANT
180864|IDN-6556-18 A Post-Treatment Follow-up Study for Liver Disease Subjects with or without Liver Cirrhosis after Receiving Emricasan or Placebo
Conatus Pharmaceuticals Inc_CPI1 Jan 2018
MORELEARN MORE
GRANT
171197|3152-201-002 STELLARIS: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evalate the Efficacy and Safety of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis
Allergan Inc_ALL10 Feb 2017
MORELEARN MORE
GRANT
170547|TARGET-NASH A 5-year Longitudinal Observational Study of Patients with Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
Target PharmaSolutions Inc_TPS1 Jan 2017
MORELEARN MORE
GRANT
171219|GS-US-384-1944 A Phase 3, randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Selonsertib in Subjects with Compensated Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)
Gilead Sciences Inc_GSI1 Jan 2017
MORELEARN MORE
GRANT
161099|GFT505-315-1 A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of Elafibranor in Patients with Nonalcoholic Steatohepatitis (NASH) and fibrosis
Covance_COV1 Jan 2016
MORELEARN MORE